Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 874

Sort by

Sort Order Select

Journal Articles

Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis

Blood Adv (2025) 9 (14): 3469–3478.

https://doi.org/10.1182/bloodadvances.2024014858

Published: 2025

Includes: Supplemental data

Journal Articles

Intrathecal chemotherapy for ciltacabtagene autoleucel–associated movement and neurocognitive toxicity

Kaitlin Kelly, Jennifer H. Cooperrider, Michael R. Bishop, Satyajit Kosuri, Andrzej Jakubowiak, Benjamin A. Derman

Blood Adv (2025) 9 (14): 3613–3616.

https://doi.org/10.1182/bloodadvances.2024015721

Published: 2025

Includes: Supplemental data

Journal Articles

Antibiotic use: impact on the microbiome and cellular therapy outcomes

Alicia Darwin, Jiayi Xie, Melody Smith

Blood Adv (2025) 9 (13): 3356–3367.

https://doi.org/10.1182/bloodadvances.2024013809

Published: 2025

Journal Articles

Throwing the microbiome out with the bathwater

Marcus Geer, Mary Riwes

Blood Adv (2025) 9 (13): 3368–3369.

https://doi.org/10.1182/bloodadvances.2025016205

Published: 2025

Journal Articles

Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022

Ajay K. Gopal, Philippe Armand, Sattva S. Neelapu, Nancy L. Bartlett, Stephen E. Spurgeon, John Kuruvilla, Kerry J. Savage, John P. Leonard, Arnold B. Gelb, Nasir Ahmed, Shiqi Dong, Sai Praneeth Bathena, Rasika Suryawanshi, Jenny Qun Wu, Sheen Wang, Douglas E. Gladstone

Blood Adv (2025) 9 (13): 3383–3394.

https://doi.org/10.1182/bloodadvances.2024015086

Published: 2025

Includes: Supplemental data

Journal Articles

Mature megakaryocytes acquire immune characteristics in a mouse model of aplastic anemia

Ashvind Prabahran, Liangliang Wu, Ash Lee Manley, Zhijie Wu, Shouguo Gao, Hiroki Mizumaki, Valentina Baena, Zulfeqhar Syed, Christian A. Combs, Jichun Chen, Xingmin Feng, Neal S. Young

Blood Adv (2025) 9 (13): 3315–3330.

https://doi.org/10.1182/bloodadvances.2024015621

Published: 2025

Includes: Supplemental data

Journal Articles

Expression and treatment of ROR1 + cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia

Paraskevi Diamanti, Bethan K. Bailey, Obinna E. Iheanacho, John P. Moppett, Amit C. Nathwani, Allison Blair

Blood Adv (2025) 9 (13): 3190–3201.

https://doi.org/10.1182/bloodadvances.2024013814

Published: 2025

Includes: Supplemental data

Journal Articles

Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution

Andreas Riedel, Laurent Phely, Stefan Hug, Philipp Faustmann, Jan Christian Schroeder, Britta Besemer, Anna M. Paczulla Stanger, Christoph Faul, Claudia Lengerke, Jan Frederic Weller, Wolfgang Bethge

Blood Adv (2025) 9 (13): 3149–3158.

https://doi.org/10.1182/bloodadvances.2024015346

Published: 2025

Includes: Supplemental data

Journal Articles

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy

Jessica S. Little, Angelica Medina Pena, E. Bridget Kim, Andrew J. Yee, Omar Nadeem, Shonali Midha, Adam S. Sperling, Nikhil C. Munshi, Noopur S. Raje, Matthew J. Frigault, Diana D. Cirstea, Sarah P Hammond

Blood Adv bloodadvances.2025016748.

https://doi.org/10.1182/bloodadvances.2025016748

Published: 2025

Includes: Supplemental data

Journal Articles

Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse

Blood Adv bloodadvances.2025016181.

https://doi.org/10.1182/bloodadvances.2025016181

Published: 2025

Includes: Supplemental data

Journal Articles

Current developments in T-cell receptor therapy for acute myeloid leukemia

Sayali Gore, Emily Blyth, Marie Bleakley, Koon Lee, Kenneth Micklethwaite, Kavitha Gowrishankar

Blood Adv (2025) 9 (12): 3069–3089.

https://doi.org/10.1182/bloodadvances.2024014105

Published: 2025

Journal Articles

The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy

Eleftheria Kampouri, Patrick Flaherty, Hu Xie, Mandeep K. Sekhon, Clementine Chalal, Terry L. Stevens-Ayers, Damian J. Green, Jordan Gauthier, Mazyar Shadman, Ailyn C. Pérez-Osorio, Keith R. Jerome, Wendy M. Leisenring, Michael J. Boeckh, Joshua A. Hill

Blood Adv (2025) 9 (12): 2997–3001.

https://doi.org/10.1182/bloodadvances.2024015164

Published: 2025

Includes: Supplemental data

Journal Articles

AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling

Blood Adv (2025) 9 (12): 2935–2952.

https://doi.org/10.1182/bloodadvances.2024015000

Published: 2025

Includes: Supplemental data

Journal Articles

Extracellular vesicles for CAR T-cell therapy immunomonitoring

Marion Klea Pinheiro, Benoît Vingert

Blood Adv (2025) 9 (12): 2920–2921.

https://doi.org/10.1182/bloodadvances.2025015988

Published: 2025

Journal Articles

CD19.CAR T-cell–derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy

Blood Adv (2025) 9 (12): 2907–2919.

https://doi.org/10.1182/bloodadvances.2024014860

Published: 2025

Includes: Supplemental data

Journal Articles

Spatial transcriptomics of progression gene signature and tumor microenvironment leading to progression in mycosis fungoides

Myoung Eun Choi, Gyeonghoon Kim, Hwa-Jeong Shin, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Woo Jin Lee

Blood Adv (2025) 9 (12): 2871–2885.

https://doi.org/10.1182/bloodadvances.2024014495

Published: 2025

Includes: Supplemental data

Journal Articles

Adult thymectomy is associated with increased mortality risk from cancer but not cardiovascular disease

Kameron Allen Kooshesh, Brody Harry Foy, Richard A Baylis, Karin Gustafsson, Daniel A Zlotoff, Tomas G Neilan, David T Scadden

Blood Adv bloodadvances.2024015286.

https://doi.org/10.1182/bloodadvances.2024015286

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Blood Adv (2025) 9 (11): 2763–2772.

https://doi.org/10.1182/bloodadvances.2024014846

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel

Blood Adv (2025) 9 (11): 2663–2676.

https://doi.org/10.1182/bloodadvances.2024013656

Published: 2025

Includes: Supplemental data

Journal Articles

Breaking the cycle: PRMTs and secondary HLH relief

Sakshi Malik, Shanmuganathan Chandrakasan

Blood Adv (2025) 9 (10): 2436–2437.

https://doi.org/10.1182/bloodadvances.2025015863

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis

Intrathecal chemotherapy for ciltacabtagene autoleucel–associated movement and neurocognitive toxicity

Antibiotic use: impact on the microbiome and cellular therapy outcomes

Throwing the microbiome out with the bathwater

Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022

Mature megakaryocytes acquire immune characteristics in a mouse model of aplastic anemia

Expression and treatment of ROR1 + cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia

Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy

Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse

Current developments in T-cell receptor therapy for acute myeloid leukemia

The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy

AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling

Extracellular vesicles for CAR T-cell therapy immunomonitoring

CD19.CAR T-cell–derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy

Spatial transcriptomics of progression gene signature and tumor microenvironment leading to progression in mycosis fungoides

Adult thymectomy is associated with increased mortality risk from cancer but not cardiovascular disease

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel

Breaking the cycle: PRMTs and secondary HLH relief

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only